Preclinical and Translational Sciences
Joshua Apgar, PhD (he/him/his)
CSO Co Founder
Applied BioMath, LLC
Concord, Massachusetts
Fei Hua, PhD
VP of Modeling and Simulation Services
Applied BioMath
Concord
For complex therapeutics, such as bispecific and multispecific molecules, ADCs, cell and gene-therapies there are many design factors that are not always straightforward. In most cases it is impractical to test the large combinatorial design space. Moreover as these modalities are highly species specific, it is challenging to evaluate their safety and efficacy preclinically. Incorporating mathematical modeling approaches provides competitive advantages, as it helps to test and generate hypotheses much more quickly than traditional methods. This session will present a series of case studies where modeling made substantial contributions to accelerating the development of safer and more efficacious drugs.